Ryan Jones
Hematology & Oncology · Bethesda, MDNPI 1720426760
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 44 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 11.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $529, 6.5 times the $81 reported in 2020. That places this record below the midpoint for hematology & oncology clinicians in MD, where the typical reported total is $2,111.
Across 44 payments — averaging $22.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Karyopharm Therapeutics Inc.$112
- Exelixis Inc.$93
- AbbVie$80
- Incyte Corporation$78
- Boehringer Ingelheim$67
- Genmab U.S., Inc.$66
- plus $508 from 16 others
Across 1 payment — averaging $26,656 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$27K
What the payments were for
- Food & beverage$97998%
- Education$242%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Karyopharm Therapeutics Inc. | 5 | $112 |
| Exelixis Inc. | 4 | $93 |
| AbbVie | 3 | $80 |
| Incyte Corporation | 4 | $78 |
| Boehringer Ingelheim | 3 | $67 |
| Genmab U.S., Inc. | 2 | $66 |
| Gilead | 2 | $62 |
| Sobi, Inc | 2 | $55 |
| Bristol Myers Squibb | 2 | $53 |
| Beigene USA, Inc. | 2 | $48 |
| Merck | 2 | $40 |
| AstraZeneca | 2 | $34 |
| Daiichi Sankyo Inc. | 2 | $29 |
| Geron Corporation | 1 | $26 |
| Sanofi | 1 | $26 |
| Fennec Pharmaceuticals, Inc. | 1 | $25 |
| Beone Medicines USA, Inc. | 1 | $22 |
| AVEO Pharmaceuticals, Inc. | 1 | $19 |
| BTG International Inc. | 1 | $19 |
| GSK | 1 | $16 |
| EMD Serono, Inc. | 1 | $16 |
| Stemline Therapeutics Inc. | 1 | $16 |
How this compares
$1,003 in reported general payments places this provider in the 40th percentile of 242 hematology & oncology providers in Maryland.
Other hematology & oncology in Bethesda
- Ralph BocciaBethesda$3.1M
- Sandra SwainBethesda$1M
- Chitra RajagopalBethesda$89K
- Susan LeitmanBethesda$44K
- Giuseppe GiacconeBethesda$32K
- Phillip ScheinbergBethesda$27K
- Steven PavleticBethesda$13K
- Kashif AliSilver Spring$987K
- Ani BalmanoukianBaltimore$842K
- Benjamin LevyBaltimore$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.